[111In]In-US2 showed high selectivity for CA-IX high-expressing (HT-29) cells in vitro, and demonstrated higher HT-29 tumor uptake at 1−4 h postinjection than other previously reported radioligands of CA-IX [26, 27, 47–52]. The gene discussed is CA9; the disease is neoplasm.